Clearside Biomedical, Inc.: Business Overview, Financials & Competitive Analysis
Clearside Biomedical, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Clearside's suprachoroidal platform and Phase 3-ready wet AMD program have acquisition appeal, but current financial distress and Chapter 11 proceedings dominate near-term risk profile. Clearside possesses differentiated delivery technology and clinically validated assets (FDA-approved XIPERE, Phase 3-ready CLS-AX), but filed Chapter 11 bankruptcy in November 2025 indicating severe financial.
What is Clearside Biomedical, Inc.'s industry? Clearside Biomedical, Inc. (clearsidebio.com) operates in Pharmaceuticals. AskCyborg classifies Clearside Biomedical, Inc. under Pharmaceuticals in its company registry.
Clearside Biomedical is a biopharmaceutical company developing therapies for back-of-the-eye diseases using its proprietary suprachoroidal space (SCS) injection platform and SCS Microinjector. The company has commerci...
Cyborg Score thesis
Clearside's suprachoroidal platform and Phase 3-ready wet AMD program have acquisition appeal, but current financial distress and...
Read the full analyst-debate transcript →Get the Latest Clearside Biomedical, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeClearside Biomedical, Inc. Overview
Pro stress-test →Clearside Biomedical is a biopharmaceutical company developing therapies for back-of-the-eye diseases using its proprietary suprachoroidal space (SCS) injection platform and SCS Microinjector. The company has commercialized XIPERE® (triamcinolone acetonide) through Bausch + Lomb for uveitic macular edema and is advancing CLS-AX (axitinib injectable suspension), a Phase 3-ready program for wet age-related macular degeneration, while operating five suprachoroidal licensing partnerships.
Strategic Profile
Pro stress-test →Clearside pioneered suprachoroidal delivery as an alternative route to treat posterior segment eye diseases, enabling targeted compartmentalized delivery with potentially fewer systemic side effects. The company operates a hybrid "Product + Platform" model: generating royalty revenue from licensing its SCS Microinjector technology to pharma and gene-therapy partners while building an internal pipeline of small-molecule assets. However, the company filed voluntary Chapter 11 bankruptcy in November 2025 to pursue a strategic sale of its platform and pipeline assets.
Competitive Landscape
Pro stress-test →Clearside competes in retinal disease treatment against larger ophthalmology players including Regeneron (wet AMD anti-VEGF therapy Eylea), Novartis (Beovu and gene therapy portfolio), Roche/Genentech (wet AMD biologics), AbbVie (retinal gene therapy through REGENXBIO partnership), and smaller specialized players like Aura Biosciences (ocular tumor gene therapy). Clearside's competitive differentiation centers on its proprietary suprachoroidal delivery mechanism, which enables targeted posterior-segment drug exposure with a simple office-based procedure. However, competitors' scale, commercial infrastructure, and established wet AMD market share present significant competitive headwinds.
Industry Context
Clearside Biomedical, Inc. operates in Pharmaceuticals.
Key facts
Founded: 2011 · Headquarters: Alpharetta, Georgia, US · Employees: 10–50 · Revenue: Estimated $5M–$10M (2024); primarily royalty-based from XIPERE and licensing partnerships